drugset
drugset / Trial / NCT05844592

First in Human, Single Ascending Dose Study

NCT05844592 ↗

Phase 1 Completed 40 enrolled Innovo Therapeutics, Inc.
RandomizedSequentialDouble-blindTreatment

Summary

The goal of this study is to evaluate the safety and tolerability of single ascending oral doses of INV-101 in healthy adult subjects.

Timeline

Start
2022-04-21
Primary completion
2022-07-16
Completion
2022-08-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator INV-101 Unknown — Oral

Indications

ulcerative colitis